Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
Pediatric patients aged five years and older with active lupus nephritis will have a treatment option for at-home administration.
Download (PDF, 249.5KB) -
Students step into the role of athletic trainers, cardiologists, dietitians, and more with free summer science program
GSK Science in the Summer™ unveils its 2025 theme: Be a Health Scientist! for students in grades 2–6 nationwide.
Download (PDF, 214.4KB) -
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus
Download (PDF, 117.8KB) -
GSK invests $450,000 in STEM education in Philadelphia public schools
Global biopharma company GSK has donated $450,000 to STEM education in Philadelphia’s public schools.
Download (PDF, 198.4KB) -
GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
Latest data on belantamab mafodotin combinations underscore the potential to transform treatment of 2L+ multiple myeloma
Download (PDF, 333.4KB) -
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype.
Download (PDF, 247.7KB) -
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options.
Download (PDF, 212.7KB) -
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime’s mom audience about meningococcal disease.
Download (PDF, 178.7KB) -
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization.
Download (PDF, 173.7KB) -
GSK’s 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices
Vaccine recommended to help protect persons over 10 years old in the US against disease-causing serogroups of Neisseria meningitidis.
Download (PDF, 196.3KB) -
GSK awards $2M in grant funding for programs supporting adult vaccination, commits additional $2M for 2025
GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education.
Download (PDF, 254.1KB) -
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients 12 years of age and older
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
Download (PDF, 154.2KB) -
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude.
Download (PDF, 161.4KB) -
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Results from the phase IIb study, EMBRACE, demonstrate that N6LS, a bNAb administered every four months.
Download (PDF, 166.3KB) -
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens.
Download (PDF, 98.3KB) -
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025
Real-world and implementation data highlight effectiveness of Cabenuva and Apretude.
Download (PDF, 248.2KB) -
PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y).
Download (PDF, 202.1KB) -
GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA
If approved, the new presentation will offer a convenient administration option to healthcare professionals.
Download (PDF, 241.4KB) -
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
Regulatory designation based on promising early data in this rare bone cancer.
Download (PDF, 144.6KB) -
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab-gxly.
Download (PDF, 306.5KB)
